Ovarian Features after 2 Weeks, 3 Weeks and 4 Weeks Transdermal Testosterone Gel Treatment and Their Associated Effect on IVF Outcomes in Poor Responders
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study was performed to investigate the effect of of transdermal testosterone gel (TTG) on controlledovarian stimulation (COS) and IVF outcomes and ovarian morphology according to pretreatment duration in poor responders. A total of 120 women were recruited for this pilot study. They were randomized into control, 2 weeks, 3 weeks or 4 weeksTTG treatment groups. For three TTG treatment groups, 12.5 mg TTG was applied daily for 2 weeks, 3 weeks or 4 weeks inpreceding period of study stimulation cycle. After 3 weeks of TTG pretreatment, significant increase of antral follicle count(AFC) and significant decreases of mean follicular diameter (MFD) and resistance index (RI) value of ovarian stromal arterywere observed (p=0.026, p<0.001, p<0.01, respectively). The total dose of rhFSH administered for COS significantlydecreased after 3 and 4 weeks TTG treatment both compared with control group (p<0.001, p<0.001). The numbers of oocytesretrieved and mature oocytes were significanty higher in 3 and 4 weeks TTG treatment groups than control group (p<0.001,p<0.001 in the number of oocytes retrieved; p<0.001, p<0.001 in the number of mature oocytes). The clinical pregnancy rateand live birth rate were increased only in 4 weeks TTG treatment group compared with control group (p=0.030 and p=0.042,respectively). These data demonstrated that TTG pretreatment for 3 to 4 weeks increases AFC and ovarian stromal blood flow,thereby potentially improving the ovarian response to COS and IVF outcome in poor responders undergoing IVF/ICSI.
Abstract
This study was performed to investigate the effect of of transdermal testosterone gel (TTG) on controlledovarian stimulation (COS) and IVF outcomes and ovarian morphology according to pretreatment duration in poor responders. A total of 120 women were recruited for this pilot study. They were randomized into control, 2 weeks, 3 weeks or 4 weeksTTG treatment groups. For three TTG treatment groups, 12.5 mg TTG was applied daily for 2 weeks, 3 weeks or 4 weeks inpreceding period of study stimulation cycle. After 3 weeks of TTG pretreatment, significant increase of antral follicle count(AFC) and significant decreases of mean follicular diameter (MFD) and resistance index (RI) value of ovarian stromal arterywere observed (p=0.026, p<0.001, p<0.01, respectively). The total dose of rhFSH administered for COS significantlydecreased after 3 and 4 weeks TTG treatment both compared with control group (p<0.001, p<0.001). The numbers of oocytesretrieved and mature oocytes were significanty higher in 3 and 4 weeks TTG treatment groups than control group (p<0.001,p<0.001 in the number of oocytes retrieved; p<0.001, p<0.001 in the number of mature oocytes). The clinical pregnancy rateand live birth rate were increased only in 4 weeks TTG treatment group compared with control group (p=0.030 and p=0.042,respectively). These data demonstrated that TTG pretreatment for 3 to 4 weeks increases AFC and ovarian stromal blood flow,thereby potentially improving the ovarian response to COS and IVF outcome in poor responders undergoing IVF/ICSI.
참고문헌 (22)
- Barad D, "Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF", Hum Reprod, 21, pp.2845~2849 (2006)
- Barbieri RL, "Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization", Fertil Steril, 83, pp.302~308 (2005)
- Casson PR, "Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series", Hum Reprod, 15, pp.2129~2132 (2000)
- de los Santos MJ, "The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypoandrogenic?", Hum Reprod, 28, pp.224~229 (2013)
- Fabregues F, "Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial", Hum Reprod, 24, pp.349~359 (2009)
- Fanchin R, "Androgens and poor responders: are we ready to take the plunge into clinical therapy?", Fertil Steril, 96, pp.1062~1065 (2011)
- Ferraretti AP, "ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria", Hum Reprod, 26, pp.1616~1624 (2011)
- Frattarelli JL, "Effect of androgen levels on in vitro fertilization cycles", Fertil Steril, 81, pp.1713~1714 (2004)
- Futterweit W, "Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals", J Clin Endocrinol Metab, 62, pp.16~21 (1986)
- Gonzalez-Comadran M, "Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis", Reprod Biomed Online, 25, pp.450~459 (2012)
- Jonard S, "Ultrasound examination of polycysticovaries: is it worth counting the follicles?", Hum Reprod, 18, pp.598~603 (2003)
- Massin N, "Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study", Hum Reprod, 21, pp.1204~1211 (2006)
- Nielsen ME, "In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA", Mol Hum Reprod, 17, pp.63~70 (2011)
- Pache TD, "Ovarian morphology in longterm androgen-treated female to male transsexuals", A human model for the study of polycystic ovarian syndrome? Histopathology, 19, pp.445~452 (1991)
- Pigny P, "Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest", J Clin Endocrinol Metab, 88, pp.5957~5962 (2003)
- Ryan KJ, "Steroid formation by isolated and recombined ovarian granulosa and tehcal cells", J Clin Endocrinol Metab, 28, pp.355~358 (1968)
- Vendola KA, "Androgens stimulate early stages of follicular growth in the primate ovary", J Clin Invest, 101, pp.2622~2629 (1998)
- Vendola K, "Androgens promote oocyte insulinlike growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 61:353-357", Biol Reprod, 61, pp.353~357 (1999)
- Wang C, "Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men", J Clin Endocrinol Metab, 89, pp.2085~2098 (2004)
- Weil SJ, "Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations", J Clin Endocrinol Metab, 83, pp.2479~2485 (1998)
- Weil S, "Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development", J Clin Endocrinol Metab, 84, pp.2951~2956 (1999)
- Zeleznik AJ, "Administration of dihydrotestosterone to rhesus monkeys inhibits gonadotropin-stimulated ovarian steroidogenesis", J Clin Endocrinol Metab, 89, pp.860~866 (2004)